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Background: Assistive technology and telecare (ATT) are relatively new ways of delivering care and support to
people with social care needs. It is claimed that ATT reduces the need for community care, prevents unnecessary
hospital admission, and delays or prevents admission into residential or nursing care. The current economic
situation in England has renewed interest in ATT instead of community care packages. However, at present, the
evidence base to support claims about the impact and effectiveness of ATT is limited, despite its potential to
mitigate the high financial cost of caring for people with dementia and the social and psychological cost to unpaid
carers.
Method/design: ATTILA (Assistive Technology and Telecare to maintain Independent Living At Home for People
with Dementia) is a pragmatic, multi-centre, randomised controlled trial over 104 weeks that compares outcomes
for people with dementia who receive ATT and those who receive equivalent community services but not ATT. The
study hypothesis is that fewer people in the ATT group will go into institutional care over the 4-year period for
which the study is funded. The study aims to recruit 500 participants, living in community settings, with dementia
or significant cognitive impairment, who have recently been referred to social services.
Primary outcome measures are time in days from randomisation to institutionalisation and cost effectiveness.
Secondary outcomes are caregiver burden, health-related quality of life in carers, number and severity of serious
adverse events, and data on acceptability, applicability and reliability of ATT intervention packages. Assessments will
be undertaken in weeks 0 (baseline), 12, 24, 52 and 104 or until institutionalisation or withdrawal of the participant
from the trial.
Discussion: In a time of financial austerity, CASSRs in England are increasingly turning to ATT in the belief that it
will deliver good outcomes for less money. There is an absence of robust evidence for the cost-effectiveness and
benefit of using assistive technology and telecare. The ATTILA trial meets a pressing need for robust, generalisable
evidence to either justify continuing investment or reappraise the appropriate scale of ATT use.
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There are approximately 800,000 people with dementia
in the UK [1], many of whom will require accommoda-
tion in nursing or residential care homes when their ill-
ness has progressed to the point at which they can no
longer live safely and independently in their own homes.
It has been estimated that over the next 2 decades the
number of people aged 85 and over will increase by two-
thirds [2]. Over half of all users of adult social care ser-
vices are aged 65 and over [3], and a steep rise in the
numbers of people living with dementia is expected over
the next few decades. The financial cost of caring for
people with dementia is considerable [1], as is the social
and psychological cost to unpaid carers (generally a rela-
tive or friend, subsequently referred to as ‘carers’). Carer
breakdown is a common reason for the unplanned
admission of older people (many of whom will have
dementia) into permanent nursing or residential care [4].
Living Well with Dementia, the theme of the 2009
National Dementia Strategy for England [5], involves hel-
ping people with dementia retain their independence
while living in their own homes as well as to maintain
their quality of their life. People living with dementia
who move from their own homes into institutional care
often experience a loss of independence and quality of
life. In order to minimize this possibility, the National
Health Service (NHS) and Councils with Adult Social
Services Responsibilities (subsequently referred to as
CASSRs) in England aim to support people with de-
mentia to live safely in their own homes for as long as
possible.
Assistive technology and telecare (ATT) offer relatively
new means of delivering care and support to people with
social care needs by helping to manage risks facing older
people with dementia who wish to remain living inde-
pendently at home. Sensors to detect falls, floods, or the
presence of gas from an unlit appliance in someone’s
home, for example; passive monitoring, for example, sen-
sors placed within a home environment to detect move-
ment; and alerting devices to relay information from the
person’s home to a remote site such as a call centre are
claimed to support the independence of people with social
care needs, to reduce the burden on unpaid carers [6-10]
and to save CASSRs money. By addressing risks associated
with independent living for people with dementia, ATT
has claimed to help reduce the need for community
care, prevent unnecessary hospital admissions, and
delay or prevent admission into residential or nursing
care. [7,11-13] The evidence to support such claims is
limited and based largely on qualitative evidence or un-
controlled quantitative studies [14,15]. There is, therefore,
an urgent need to provide evidence to inform decisions
about whether to provide ATT in the homes of people
with dementia. ATTILA is designed to answer questionsabout the efficacy and cost-effectiveness of ATT, with rele-
vance for those who commission and provide care for
people with dementia.
Research evidence
The first use of electronic ATT in the UK, in the 1990s,
was to provide support for people with dementia and
their carers [11,16-19]. Within a decade, interest in ATT
has developed from a fringe interest for a handful of
enthusiasts to a multi-million pound industry comman-
ding government support, a Department of Health stra-
tegy [20] and, increasingly, the use of ATT in CASSR
settings as a mainstream service (see, for example [19]).
However, as interest in ATT has increased, the specific
focus on its application for those living with dementia
has diminished [8]. The performance indicators that
followed the Preventive Technology Grant (given to
CASSRs in 2008 by the Department of Health [20]) were
intended to promote the widest possible use of telecare.
The Department of Health did not, however, offer a clear
indication of what this grant was supposed to ‘prevent’.
Although Woolham [7] has drawn attention to the cost-
effectiveness of telecare for people with dementia by
closely matching ATT with assessed need, and thereby
preventing the need for more expensive forms of care,
Poole [21] has argued that CASSRs should see ATT as a
long-term investment, deploying it at an early stage with-
out expecting immediate savings. This has contributed to
a situation in which CASSRs have implemented ATT
across several different care groups without always refer-
ring to the needs of the specific groups, such as people
with dementia. The current economic situation, as well
as a significant reduction in government CASSR funding,
has led to increasing numbers of CASSRs developing an
interest in ATT. Some have developed local strategies to
use it, whilst others already have well-developed ATT
services that can be deployed alongside, or instead of,
non-institutional forms of support, often known as
‘community care’ within the UK.
Despite growing ATT use, the evidence to support its
use is limited. The Whole System Demonstrator study
(WSD) was funded by the Department of Health in 2008
to investigate the impact and effectiveness of ATT in
England [22-27], Steventon A, Bardsley M, Billings J,
Dixon J, Doll H, Beynon M, Hirani S, Cartwright M,
Rixon L, Knapp M, Henderson C, Rogers A, Hendy J,
Fitzpatrick R, Newman S: The effect of telecare on the
quality of life and psychological well-being of elderly re-
cipients of social care over a 12 month period – the
whole systems demonstrator (WSD) cluster randomised
trial, forthcoming, Henderson C, Knapp M, Fernández JL,
Beecham J, Hirani S, Beynon M, Cartwright M, Rixon L,
Doll H, Bower P, Steventon A, Rogers A, Fitzpatrick R,
Barlow J, Bardsley M, Newman S, Whole System
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care for people with social care needs: the whole systems
demonstrator cluster randomised trial, forthcoming].
However, individuals with dementia were not specifically
included. This, together with the relative dearth of
dementia-specific studies in ATT, means that a signifi-
cant gap remains in our evidence. Although there are
relatively large numbers of qualitative studies, audits
and service evaluations, there are few studies with suf-
ficient rigour and appropriate design to offer any de-
gree of generalisability [15] or agreement about how
‘success’ can be measured [28]. One study has sug-
gested that, when used appropriately, ATT is highly
cost-effective. Unfortunately, limitations in design and
methodology constrain the generalisability of this study’s
findings [19]. Evidence from a well-designed study such
as ATTILA may therefore also be used to guide future
policy direction.
Policy guidance
The Department of Health in England’s ‘Building Telecare’
strategy in 2005 [20] provided generic advice to CASSR.
As part of this strategy, a Preventive Technology Grant,
which CASSRs were required to spend on developing
local ATT services, was made available. England’s 2009
National Dementia Strategy [14] recommended a ‘watch-
ing brief ’ for emerging evidence of the impact of telecare,
stating:
However, with respect to more recent innovations,
this is not an area where the strategy is able at this
time to make specific recommendations. Instead,
central, regional and local teams should keep in
touch with initiatives in the areas of housing and
telecare and make appropriate commissioning
decisions as data become available, for example
from the Department’s large-scale field trials of
telecare and assistive technology. Department of
Health (2009) p. 56
Aim of the study
The aims of the ATTILA trial are to test the following
hypotheses:
 That the application of ATT will significantly extend
the time that people with dementia can continue to
live independently and safely in their own homes.
 That ATT interventions are cost-effective in the
management of risk and maintenance of
independence in people with dementia living in their
own homes.
 That provision of ATT interventions to people with
dementia living at home will significantly reduce the
number of incidents involving serious risks to safetyand independent living, particularly those involving
acute admissions to hospital,
 That ATT interventions will reduce burden and
stress in family and other unpaid carers and increase
quality of life for people with dementia.
Objectives
These hypotheses will be tested by the following primary
and secondary objectives:
Primary objectives
To establish whether ATT assessments and interventions
extend the time that people with dementia can continue
to live independently in their own homes and whether
this is cost-effective.
Secondary objectives
(1)To establish whether these technologies can
significantly reduce the number of incidents involving
serious risks to safety and independent living,
including acute admissions to hospital.
(2)To reduce burden and stress in family and other
unpaid carers; and increase quality of life for people
with dementia and their unpaid carers.
(3)To collect qualitative and quantitative data from
people living with dementia, their paid and unpaid
carers, and members of the NHS and CASSR teams
about their experience of using these technologies.
Methods
Design
ATTILA is a pragmatic randomised controlled trial over
104 weeks. Blinding will not be undertaken as it is not
feasible. It will be conducted in the homes of people living
with dementia and who are eligible to receive a package of
social care through CASSRs. The trial will compare out-
comes in two groups of participants randomised to one of
two study arms: either (1) receiving an ATT needs assess-
ment, followed by the installation of ATT devices and re-
sponse services which will be deployed by the CASSR, or
(2) receiving a semi-structured ATT needs assessment,
followed by the installation of an ATT package restricted
to only smoke and carbon monoxide detectors and a
pendant alarm if indicated, also arranged by CASSRs.
The key outcomes will be time to institutionalisation
and cost-effectiveness of the intervention.
The trial is not funded to source, assess the need for
or deploy ATT. Our approach is therefore to work
alongside CASSRs that have been charged by the De-
partment of Health with responsibility for establishing
and developing local ATT services.
The study has been approved by the NHS Health Re-
search Authority National Research Ethics Committee
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with the ISRCTN (http://www.controlled-trials.com/
ISRCTN86537017).
Planned inclusion and exclusion criteria
Inclusion criteria
Participants will be people with dementia or evidence of
cognitive difficulties significant enough to suggest the
presence of dementia without having been formally diag-
nosed as having dementia, both with and without cap-
acity. This will include those with young or later-onset
dementia. Additionally, all participants must fulfil the
following criteria:
 Meeting England’s eligibility criteria for access to
social care services FACS (Fair Access to Care
Services);
 Living in an ordinary community dwelling
(including sheltered and very sheltered
accommodation);
 Have a working telephone line in their home.
Exclusion criteria
People ineligible to take part will be those:
 Receiving an ATT intervention already (excluding
the sole provision of smoke, carbon monoxide or
pendant alarms) or where ATT has previously been
provided but has not been used;
 Being unlikely to comply with follow-up, e.g.
because of an unstable medical condition;
 Participating in another clinical trial involving an
intervention for dementia;
 Having an urgent need for a care package due to
immediate and severe risks to themselves or others.
Recruitment/consent procedures
There will be several routes for participant recruitment.
NHS services (mental health or otherwise) will likely be
the first-line sources for recruitment. We will extend re-
cruitment beyond the NHS to local social services and
include all people with dementia assessed through the
FACS processes (as did the WSD) [23]. Those referred
from the NHS will have to meet FACS eligibility and
those referred via CASSRs will either have a diagnosis of
dementia or evidence of severe memory impairment.
Participating CASSRs will, after assessing FACS eligi-
bility, ask all FACS-eligible referrals who may meet the
other ATTILA trial eligibility criteria if their contact de-
tails can be made available to a named individual in a
local ATTILA research team. Once identified, they will
be registered with the ATTILA Study Office. A member
of the local research team will contact this person and
recruit them according to the trial standard operatingprocedures, followed by the appropriate randomisation
procedures.
Consent will be sought using a defined protocol that
meets the requirements of England’s Mental Capacity
Act (2005), and where appropriate, data sharing agree-
ments will previously have been agreed with the CASSR
concerned to ensure that the transfer of personal data
from the CASSR to the research team is lawful. If con-
sent is not given, the individual will not be recruited and
all of their personal data will be removed from research
team records and destroyed.
For FACS-eligible participants who come from CASSRs,
referrers will contact the local ATTILA study centres,
which will arrange for a researcher to visit the prospective
participant to explain the study and check eligibility to
take part in the trial. If there is an urgent need for com-
munity or other forms of care or support services, then
consent will be sought at that visit so that the prospective
participant can be immediately randomised. If an urgent
need for social services is not apparent, then information
about the study will be left with the prospective partici-
pant and the researcher will return 24 h later to obtain
consent to participate in the study. The participant will
then be randomised. After randomisation, assessment for
ATT and for provision of ATT services (within limits set
by randomisation) will be left entirely to the local social
services authority concerned. Participants who come
from the NHS will only be eligible once FACS eligibility
has been established by the CASSR.
Assessments
Assessments will be undertaken by local investigators
employed by the ATTILA team in weeks 0 (baseline),
12, 24, 52 and 104. All local investigators are researchers
with clinical experience.
Following an assessment of mental capacity (and
therefore ability to consent), confirmation of eligibility
to take part, the consent process and randomisation,
both groups will receive an initial assessment using the
following scales: the Bristol Activities of Daily Living
Scale (BADLS) [29], Standardised Mini-mental State Exam
(SMMSE) [30,31], the Client Services Receipt Inventory
(CSRI) [32], The Model of Human Occupation Screening
Tool (MOHOST) [33] and the EuroQol EQ-5D [34]. Un-
paid carers of participants will be assessed over the same
intervals using the Zarit Burden Inventory (ZBI) [35],
The Centre for Epidemiological Studies Depression
Scale (CES-D10) [36], the State Trait Anxiety Inven-
tory (STAI-6) [37], the Short Form Health Survey (SF-12v2)
[38] and the Carer Technology Acceptance Questionnaire
(SUTAQ) [39]. All of the outcome measures have estab-
lished validity and high levels of inter- and intra-rater reli-
ability. No pre-testing before randomisation is possible
because of concerns by local authority hosts that this will
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may have urgent needs for support.Primary outcome measures
Time in days from randomisation to institutionalisation
This is defined as the permanent transition of the indi-
vidual from living in their own home to nursing or resi-
dential care home or to admission to an acute care
facility that results in permanent placement in a residen-
tial care or nursing home.Cost-effectiveness
Costs will be calculated by attaching nationally applic-
able unit cost measures to health and social service use
(collected at intervals stated above for each participant
using a modified version of the CSRI), using national
figures taken from the Personal Social Services Research
Unit (PSSRU) annual compendium [40] where available.
The costs of ATT will be calculated anew for those ser-
vices provided, and in this we will be guided by methods
and experience gained in the WSD trial of telecare and
telehealth [25]. Data on carer time and task inputs will
come from the CSRI, and will be valued using two ap-
proaches (replacement wage and opportunity cost) and
then comparing the results in sensitivity analyses.
Cost-effectiveness analyses will be of two types to take
into account the complication that the primary outcome
(time to institutionalisation) is itself partly an indicator
of resource use. Each type of analysis will then be con-
ducted from each of two perspectives: for the ‘formal’
health and social care system (which is, for example, the
perspective employed by the National Institute for
Health and Care Excellence in England and Wales to ap-
praise health technologies as a basis for producing
clinical guidelines [41]) and for society as a whole (which
would then additionally include the value of carer time
and any productivity losses from disrupted employment,
either for the person with dementia or the carer).
The first type of cost-effectiveness analysis will meas-
ure costs only up to the point at which a study partici-
pant goes into a care home or hospital and not beyond
(‘community costs’) and will then examine cost-effectiveness
in achieving the primary outcome (days from randomisation
to institutionalisation in the two year period). This analysis
will show the incremental cost of community-based support
for each additional institutional day avoided. The second
type of analysis will measure costs for the whole 2-year
period, including costs of care home and hospital stays
(‘total costs’), and will then examine cost-effectiveness
where the outcome is EQ-5D change, also over the 2-year
period. We will also use the EQ-5D to generate Quality-
Adjusted Life Year (QALY) measures by attaching societal
weights [42].We will compute incremental cost-effectiveness ratios
and plot cost-effectiveness acceptability curves, which
will be generated from the net benefit approach and
using bootstrap regression for a range of values of
willingness to pay for the corresponding outcomes. In
each case, we will also be able to carry out these analyses
at 24 and 52 weeks.
Secondary outcome measures
Burden in carers
We will measure both burden associated with care-giving
and levels of psychological distress among the principal
carers of participants at baseline, 12, 24, 52 and 104 weeks
using the 22-item short version of the ZBI [35].
Quality of life
We will measure health-related quality of life in carers
using the SF-12v2 [38].
Number and severity of serious adverse events
As in any trial, serious adverse events (requiring GP or
hospital care) will be recorded and reported. Details of
how we propose to do this are presented below in
Sect. 6, which deals with safety monitoring procedures.
Quantitative and qualitative data
Data on acceptability, applicability and reliability of ATT
intervention packages will be collected using the SUTAQ.
This questionnaire is currently being validated using data
from the WSD. We will collect unpaid carers’ experiences,
which will provide examples of ways in which their lives,
well-being and care-giving roles may have been enhanced
and/or undermined by the use of these technologies. Vari-
ation in their experiences and the reasons for this vari-
ation will be explored through semi-structured interviews
with individuals from groups purposively sampled to
maximize diversity of types of carer characteristics from:
(1) carers who have used the ATT for at least 6 months,
(2) carers who have requested ATT withdrawal after in-
stallation and (3) carers who have refused ATT when
offered. To achieve theoretical saturation (the point at
which no new themes emerge), at least ten participants
will be interviewed from each group, with up to a fur-
ther five from each if needed [43].
Statistics
Sample size calculation
On average, 50% of participants with a BADLS score
of >15 will enter residential care after 24 months [44]. A
reduction in the estimated 24-month transition to care
home rate by 30% (i.e. 50% institutionalised at 2 years
reduced to 35%) would require the involvement of 500
participants allowing for 10% attrition due to death
while still living in a community setting. This equates to
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for participants receiving ATT. The trial would therefore
be powered to detect a mean institutional delay of a little
less than 8 weeks. Expert opinion suggests that 8 weeks
is close to the minimum clinically important difference
in delaying institutionalisation [45].
Analyses
Statistical analysis will be by intention to treat (ITT). All
participants who are randomised will be included in the
comparison and analysed according to their randomised
allocation, including those who discontinue the ATTILA
study. Wherever possible, we will continue to collect
follow-up data from these participants after they leave
the study, so that the data set will be as complete as
possible.
The primary outcome of time to institutionalisation
will be analysed using standard log rank methods and
will include all events, even those occurring after 2 years.
Continuous outcome measures, e.g. health-related qua-
lity of life and functional ability measures, will be ana-
lysed using repeated measures regression techniques to
maximise statistical power. Exploratory subgroup ana-
lyses will be undertaken, with appropriate caution, to in-
vestigate any influence of the baseline prognostic factors
(gender, age, risk profile, support structure) on outcome.
For qualitative data, thematic analysis of transcripts
and field notes will be undertaken to develop themes
emerging inductively from data and narrative analysis of
longitudinal elements to identify and contextualise ac-
ceptable and less-acceptable practices and features of AT
equipment use. A collaborative analytic strategy will
involve appropriate research team members and ser-
vice user/carer researchers to enhance validity and to
help integrate qualitative and quantitative findings. This
component will be subject to a supplementary applica-
tion for ethical review.
Local, site-specific reports will be produced by each
local ATTILA research site towards the end of the field-
work period. The timing of reports and locally specific
content will be locally discussed and negotiated between
the local PI and designated senior managers within the
local CASSR.
Handling of potential bias and heterogeneity across
centres Since there may be some heterogeneity in the
practice of the research workers in identifying ATT
needs across the different centres, between-centre het-
erogeneity will be explored in stratified analyses.
Because ATTILA is not a blinded study, it is conceiv-
able that participants in the control group may be of-
fered ATT by CASSR staff because they believe that
risks to safety or independence might be better managed
in this way, to delay or prevent institutionalisation. As asafeguard against such potential outcome bias, we will
collect detailed data on ‘cross-overs’ in the control arm
and reasons for this: in particular whether the cross-over
is due to high risk incidents and the introduction of
ATT is seen as an alternative to institutional care. To iden-
tify such potential outcome bias we will undertake sensiti-
vity analyses, counting such participants as equivalent to
meeting the primary outcome (i.e. equivalent to institutio-
nalisation). However, the design of the study is pragmatic
and the primary analysis will be restricted to actual cases
of institutionalisations as awareness that the patient is, or
is not, receiving these technologies will be just one of the
complex factors that underlie institutionalisation.
Handling of missing data Reasons for withdrawing
from the study will be collected and, since stopping the
ATTILA intervention is likely to be informative (e.g. a
failure of or intolerance to the intervention), this infor-
mation will be used in sensitivity analyses to investigate
and reduce the impact of missing data.
Handling of reports of death It is likely that a substan-
tial number of deaths may occur amongst participants
who have been previously institutionalised and therefore
will have met the primary outcome. For deaths among
participants resident in the community, deaths that
occur as a consequence of an identified risk that the
ATT might have affected will be included as a secondary
outcome measure (documented as a serious adverse
event) and the number of identified un-related deaths in
the two study groups will be compared in the overall
analysis and included in a sensitivity analysis of the pri-
mary outcomes.
Competing risk analysis At baseline, we will collect
data on the categories of risk (e.g. safety within the
home or wandering) and the recommended ATT inter-
vention to protect against this risk. In cases where two
types of technology are recommended that might both
reduce a particular risk, we will undertake competing
risk analyses to try to disentangle the relative efficacy of
each intervention. We will enhance statistical power for
such analyses by reviewing each institutionalised patient
to classify the contribution of particular risk behaviours
to the participant’s transition to institutional care.
Ethical considerations
There are important ethical issues to be considered in
any research involving people who are living with a diag-
nosis of dementia.
Ethics and randomised controlled trial (RCT) design
Although there is some research evidence to suggest
ATT may have benefits, most of this evidence is based
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this evidence supports the use of assistive technologies
in maintaining safety in some specific cases and situa-
tions, it is insufficient to support conclusions that effec-
tiveness and utility of ATT have been established. For
this reason, we consider that it is ethical to conduct a
trial as we have proposed here, to provide more defini-
tive evidence about the impact of ATT on the lives of
people with dementia and their carers.
Seeking consent We will assume that consent is not an
‘event’ but a process. We will therefore actively seek
reaffirmed consent on all the occasions that we contact
participants and seek their data.
Release of personal data by the CASSR We will, de-
pending on the wish of the CASSR, either agree to a
data exchange protocol to allow for the exchange of per-
sonal data or introduce a simple protocol to the FACS
assessment procedures in the CASSR over the recruit-
ment period. Social work practitioners will ask newly re-
ferred, and eligible, people for their permission for their
contact details to be released to us so that we can con-
tact them.
Informed consent It will be made clear to potential par-
ticipants and their carers what taking part in the study
will entail, that they are not obliged to take part in the
trial and that the care that they will continue to receive
from the NHS and local CASSR teams will not be ad-
versely affected if they choose not to participate or wish
to withdraw from the trial at any point.
Mental capacity A diagnosis of dementia does not ne-
cessarily mean that the potential participant cannot con-
sent to take part in the study and careful, but tactful
checks will be made to establish their capacity to con-
sent. When the person does not have capacity to con-
sent, we will seek to identify someone known to the
participant who would be prepared to act as the partici-
pant’s consultee, within the meaning of England’s Mental
Capacity Act (2005).
Case accountability Legal responsibility for the
provision of services will rest at all times with the host
CASSR in each study site. We will record the type and
amount of care services, care support and ATT pro-
vided, but we will not intervene in the way in which
these services are deployed (unless our advice is sought
by the host CASSR). We recognise the concerns of some
participants, their carers and staff about the ethics of
withholding ATT, particularly as in some sites, ATT is
being actively promoted as beneficial. CASSR staff will
therefore, in practice, retain the right to suggest, forexample, that participants in either the intervention or
control group be admitted into nursing or residential
care, or, in the case of control participants, recommend
ATT if they feel that without it, the person’s ability to re-
main living safely in the community would be jeopar-
dised. The research team will monitor for adverse
incidents and will act to withdraw any participant if they
assess that it is not in the best interests of the participant
to continue in the study. The Independent Data Monito-
ring Committee (IDMC) will meet to review all adverse
events’ data together with effectiveness and efficacy data
at least every 6 months and will recommend discontinu-
ing the trial prematurely if it becomes apparent from
primary outcome data that efficacy has been established
or that the frequency of adverse events indicates that
effectiveness of the intervention is overwhelmingly likely.
Participant benefit In practice, participants in studies
of this kind benefit from taking part as involvement can
produce positive effects. Our objective, however, is to
produce evidence that will provide a robust basis for ser-
vice development and will therefore benefit people living
with dementia and their carers. The study team has the
appropriate skills and experience in conducting clinical
trials with people with dementia and includes those with
specific expertise in the use and evaluation of ATT in
dementia, statistics, health economics evaluation and so-
cial research methodologies. The team is distributed
over a number of large population centres, which will
enable the recruitment of the relatively high numbers of
participants that the trial design requires. Large-scale
clinical trials are expensive to conduct but are needed to
provide the definitive answers that important clinical
questions required so as to develop and implement
clinically and cost-effective interventions within the
NHS and CASSRs in England.
Discussion
ATT is promoted by the Department of Health in England
as a means of supporting older people at home. ATT is
increasingly being offered as a mainstream service, and
investment in this technology by CASSRs is increasing
rapidly in the belief that it will save money. At present
there is limited evidence to support this view. The only
existing RCT evidence (from the WSD) did not specifi-
cally include people with dementia. The needs of this
group mean that ATT will need to be deployed differently,
and the impact of ATT may also be different compared to
people without dementia. At a time of economic austerity,
the provision of ATT may not, in fact, be cost-effective. If,
however, ATT is shown to help people with dementia
remain independent and improve their health-related
quality of life, as well as being cost-effective, then in-
vestment in ATT will be fully justified.
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